A Phase 3, Randomized, Multi-center, Active-Controlled, Open-label Study to Evaluate the Efficacy and Safety of Peginterferon Alfa-2b (40kD, Y Shape) in Combination With Ribavirin in Chinese Chronic Hepatitis C Patients
Phase of Trial: Phase III
Latest Information Update: 08 Oct 2014
At a glance
- Drugs Peginterferon alfa-2b (Primary) ; Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C
- Focus Registrational; Therapeutic Use
- Sponsors Xiamen Amoytop Biotech
- 06 Oct 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 06 Aug 2013 Planned end date changed from 1 Apr 2015 to 1 Oct 2014 as reported by ClinicalTrials.gov.
- 03 Jan 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.